Iovance Biotherapeutics
IOVA
IOVA
122 hedge funds and large institutions have $1.31B invested in Iovance Biotherapeutics in 2018 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 52 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
185% more capital invested
Capital invested by funds: $461M → $1.31B (+$852M)
40% more funds holding
Funds holding: 87 → 122 (+35)
7.58% more ownership
Funds ownership: 79.36% → 86.94% (+7.6%)
Holders
122
Holding in Top 10
9
Calls
$7.71M
Puts
$1.57M
Top Buyers
| 1 | +$50.3M | |
| 2 | +$47.7M | |
| 3 | +$38.6M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.5M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$28.4M |
Top Sellers
| 1 | -$24.1M | |
| 2 | -$12.7M | |
| 3 | -$9.87M | |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$5.02M |
| 5 |
Millennium Management
New York
|
-$2.35M |